Brought to you by 
GSK gets cancer immunotherapies from Ludwig Institute
09 Nov 2021
Executive Summary
The Ludwig Institute for Cancer Research has licensed GlaxoSmithKline rights to a group of antigens expressed in various cancers including melanoma and non-small cell lung, breast, head and neck, bladder, and liver cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK gets cancer immunotherapies from Ludwig Institute
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice